Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGMT methylation: A marker of response to temozolomide in low‐grade gliomas

1 Dec 2006

Abstract excerpt

The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide. Methylated MGMTP was detected in 63 of 68 (92.6 %) patients and was a favorable predictor of progression-free survival as compared with unmethylated MGMTP tumors (p < 0.0001). Assessment of MGMTP status could help identifying low-grade gliomas patients more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17192931
DOI: 10.1002/ana.21044

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGMT methylation: A marker of response to temozolomide in low‐grade gliomasPMID 17192931Read ↗

O 6 -methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: A review of current statusSemantic proximity Read ↗

Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatmentSemantic proximity Read ↗

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to TemozolomideSemantic proximity Read ↗

CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary GliomasSemantic proximity Read ↗

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Semantic proximity Read ↗

MGMT promoter methylation in plasma of glioma patients receiving temozolomideSemantic proximity Read ↗

MGMT Promoter Methylation: Prognostication beyond Treatment ResponseSemantic proximity Read ↗

Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating ChemotherapySemantic proximity Read ↗

O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter MethylationSemantic proximity Read ↗

A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the<i>O</i>6-Methylguanine-DNA Methyltransferase PromoterSemantic proximity Read ↗

Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort studySemantic proximity Read ↗

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.